### Clinical Extent of Disease before any treatment

- **Primary Tumor (T)**
  - **T0**: No evidence of primary tumor
  - **T1**: Solitary tumor without vascular invasion
  - **T2**: Solitary tumor with vascular invasion or multiple tumors none more than 5 cm
  - **T3a**: Multiple tumors more than 5 cm
  - **T3b**: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein
  - **T4**: Tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum

- **Regional Lymph Nodes (N)**
  - **NX**: Regional lymph nodes cannot be assessed
  - **N0**: No regional lymph node metastasis
  - **N1**: Regional lymph node metastasis

- **Distant Metastasis (M)**
  - **M0**: No distant metastasis (no pathologic M0; use clinical M to complete stage group)
  - **M1**: Distant metastasis

### Pathologic Extent of Disease through completion of definitive surgery

- **Primary Tumor (T)**
- **Regional Lymph Nodes (N)**
- **Distant Metastasis (M)**

### Anatomic Stage • Prognostic Groups

<table>
<thead>
<tr>
<th>GROUP</th>
<th>T</th>
<th>N</th>
<th>M</th>
<th>GROUP</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
<td>I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>II</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>IIIA</td>
<td>T3a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IIIB</td>
<td>T3b</td>
<td>N0</td>
<td>M0</td>
<td>IIIC</td>
<td>T4</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IVA</td>
<td>any T</td>
<td>N1</td>
<td>M0</td>
<td>IVA</td>
<td>any T</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td>IVB</td>
<td>any T</td>
<td>any N</td>
<td>M1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Prognostic Factors (Site-Specific Factors)

**Required for staging:** None

**Clinically significant:**
- Alpha Fetoprotein (AFP)
- Fibrosis Score
- Hepatitis Serology
- Creatinine (part of the Model for End Stage Liver Disease score)
- Bilirubin (part of the Model for End Stage Liver Disease score)
- Prothrombin time international normalized ratio (INR) (part of the Model for End Stage Liver Disease score)

### General Notes

For identification of special cases of TNM or pTNM classifications, the ‘m’ suffix and ‘y,’ ‘r,’ and ‘a’ prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

**m suffix** indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
Histologic Grade (G) (also known as overall grade)

Grading system

- 2 grade system
- 3 grade system
- 4 grade system
- No 2, 3, or 4 grade system is available

<table>
<thead>
<tr>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade I or 1</td>
</tr>
<tr>
<td>Grade II or 2</td>
</tr>
<tr>
<td>Grade III or 3</td>
</tr>
<tr>
<td>Grade IV or 4</td>
</tr>
</tbody>
</table>

ADDITIONAL DESCRIPTORS

Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists’ (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- Lymph-Vascular Invasion Not Present (absent)/Not Identified
- Lymph-Vascular Invasion Present/Identified
- Not Applicable
- Unknown/Indeterminate

Residual Tumor (R)
The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

Clinical stage was used in treatment planning (describe): ____________________________

National guidelines were used in treatment planning

- NCCN
- Other (describe): ____________________________

Physician signature

Date/Time

Hospital Name/Address

Patient Name/Information

(continued from previous page)
**Illustration**
Indicate on diagram primary tumor and regional nodes involved.

<table>
<thead>
<tr>
<th>HOSPITAL NAME/ADDRESS</th>
<th>PATIENT NAME/INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>